Manufacturer-sponsored prescription drug coupons may offer immediate savings at the pharmacy counter, but patients with commercial insurance should carefully consider whether using them will backfire through hidden costs and deductible strategies.
Patients with commercial insurance have slowed their use of manufacturer-sponsored drug coupons in recent years, even as prescription drug costs rise, according to a study published April 6 by the Journal of the American Medical Association. Coupons offered directly by manufacturers differ from discount card services like GoodRx, which negotiate lower bulk prices; manufacturers issue coupons to keep their drugs competitive by offering patients short-term savings and encouraging use of brand-name versions over cheaper generics.
The decision to use a coupon depends on insurance status. Uninsured patients may save money with coupons, particularly when no generic version exists. A new federally funded initiative called TrumpRx acts as a prescription drug coupon dashboard for uninsured patients. Michelle Long, a senior policy manager at KFF, said people without insurance “could have some real savings,” though TrumpRx lists only about 85 drugs among thousands approved by the FDA.
For people with commercial insurance, the answer is more complicated. If the drug isn’t covered by an insurance plan or the patient intends to pay cash, a coupon may help. However, insurers use strategies to discourage coupon use. “Copay accumulators” allow coupon use but don’t count the coupon value toward deductibles or out-of-pocket maximums, making it harder for patients to reach the threshold for insurance coverage. “Copay maximizers” prevent coupon value from counting toward deductibles and adjust patients’ copayments over the year to match manufacturers’ coupons. Initially, consumers see savings at the pharmacy counter but may pay more long-term.
Coupon use on obesity drugs specifically has plummeted. Kang’s study found that coupon use by commercial insurance holders on GLP-1 obesity drugs dropped from 54.6% of prescriptions in 2017 to only 2.5% in 2024, reflecting more patients paying cash as prices decline and insurers’ reluctance to cover them.
For patients expecting high medical costs, using coupons might make sense if they’ll meet their deductible anyway. Conversely, patients with insurance and low overall medical costs should almost always skip the coupon unless the drug is uncovered.
Medicare and Medicaid beneficiaries are prohibited from using manufacturer-sponsored coupons due to federal anti-kickback laws. Some states like California and Massachusetts prohibit or limit coupon use when a generic version is available.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.timescall.com/2026/05/16/that-discount-at-the-pharmacy-counter-may-pack-hidden-costs/